Nanobiotix (NASDAQ:NBTX – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.58) per share and revenue of $3.55 million for the quarter.
Nanobiotix Stock Performance
Shares of NASDAQ NBTX opened at $3.62 on Friday. The company has a 50 day simple moving average of $3.51 and a 200-day simple moving average of $3.90. Nanobiotix has a 1 year low of $2.76 and a 1 year high of $7.51.
Analyst Ratings Changes
Separately, UBS Group raised shares of Nanobiotix to a “hold” rating in a research report on Monday, February 17th.
Nanobiotix Company Profile
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than Nanobiotix
- Best Stocks Under $10.00
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Growth Stocks: What They Are, Examples and How to Invest
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Stock Market Upgrades: What Are They?
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
